Industry News
Biotechnology Industry News
Improving RNA editing for genetic diseases by recruiting the body’s natural protein
Improving RNA editing for genetic diseases by recruiting the body’s natural protein aliu Mon, 02/14/2022 - 09:51
Roivant decants another Vant armed with Eisai blood cancer drug and plans to start phase 1/2 soon
Roivant decants another Vant armed with Eisai blood cancer drug and plans to start phase 1/2 soon ntaylor Mon, 02/14/2022 - 08:35
FDA fingers tox assessment as cause of Denali clinical hold, leaving biotech with a to-do list to regain momentum
FDA fingers tox assessment as cause of Denali clinical hold, leaving biotech with a to-do list to regain momentum ntaylor Mon, 02/14/2022 - 07:51
Editor’s Corner: Fierce Biotech gets a fierce makeover
Editor's Corner: Fierce Biotech gets a fierce makeover aarmstrong Fri, 02/11/2022 - 15:14
Roche, Lilly push back against CMS painting their Alzheimer’s meds with the same brush as Biogen’s Aduhelm
Roche, Lilly push back against CMS painting their Alzheimer’s meds with the same brush as Biogen’s Aduhelm aarmstrong Fri, 02/11/2022 - 12:40
ProQR shares plummet as eye disease treatment flops phase 2/3 pediatric trial
ProQR shares plummet as eye disease treatment flops phase 2/3 pediatric trial mbayer Fri, 02/11/2022 - 10:47
Ex-FDA interim chief Giroir rejoins biotech world with eyes on $50M fundraising for new infectious disease company
Ex-FDA interim chief Giroir rejoins biotech world with eyes on $50M fundraising for new infectious disease company klahucik Fri, 02/11/2022 - 09:57
Cassava scores a win as FDA declines to intervene in petition to stop its Alzheimer’s drug trials
Cassava scores a win as FDA declines to intervene in petition to stop its Alzheimer's drug trials aarmstrong Fri, 02/11/2022 - 09:36
Metacrine lays off half its staff, mainly researchers, and ditches more work to focus on IBD after NASH disaster
Metacrine lays off half its staff, mainly researchers, and ditches more work to focus on IBD after NASH disaster klahucik Fri, 02/11/2022 - 09:27
Hunting for cutting-edge biotech, Fujifilm sets up early-stage VC fund
Hunting for cutting-edge biotech, Fujifilm sets up early-stage VC fund ntaylor Fri, 02/11/2022 - 05:43
With approval in sight, ObsEva sells regional rights to women’s health drug for tiny upfront
With approval in sight, ObsEva sells regional rights to women’s health drug for tiny upfront ntaylor Fri, 02/11/2022 - 04:50
Vivocore combines InterVivo, Transpharmation to form neuroscience CRO with an interest in psilocybin
Vivocore combines InterVivo, Transpharmation to form neuroscience CRO with an interest in psilocybin mbayer Thu, 02/10/2022 - 14:40
Curevo will go head-to-head against GSK’s Shingrix thanks to new $60M financing
Curevo will go head-to-head against GSK's Shingrix thanks to new $60M financing mbayer Thu, 02/10/2022 - 11:38
FDA denies Ardelyx’s appeal against kidney drug rejection, hammering another nail in tenapanor’s coffin
FDA denies Ardelyx’s appeal against kidney drug rejection, hammering another nail in tenapanor’s coffin ntaylor Thu, 02/10/2022 - 08:13
AstraZeneca dumps late-phase, next-gen COVID-19 vaccine, calling time on a beta player in an omicron world
AstraZeneca dumps late-phase, next-gen COVID-19 vaccine, calling time on a beta player in an omicron world ntaylor Thu, 02/10/2022 - 05:29
Indapta snags $50M financing and signs on former Juno exec as CEO
Indapta snags $50M financing and signs on former Juno exec as CEO mbayer Wed, 02/09/2022 - 14:51
Engineered TCR-T cells by Fred Hutch, San Raffaele-Intellia fend off evasive leukemia, solid tumors
Engineered TCR-T cells by Fred Hutch, San Raffaele-Intellia fend off evasive leukemia, solid tumors aliu Wed, 02/09/2022 - 11:41
Checkmate plucks BMS exec Bash to be new CEO
Checkmate plucks BMS exec Bash to be new CEO mbayer Wed, 02/09/2022 - 10:12
Rivus throws down mid-stage liver fat data on quest to climb NASH mountain
Rivus throws down mid-stage liver fat data on quest to climb NASH mountain aarmstrong Wed, 02/09/2022 - 09:36
Chasing Novartis and Roche, Ventus banks $140M to take inflammatory disease drug into the clinic
Chasing Novartis and Roche, Ventus banks $140M to take inflammatory disease drug into the clinic ntaylor Wed, 02/09/2022 - 08:14